tradingkey.logo

BRIEF-Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

ReutersJan 6, 2025 11:20 PM

- Denali Therapeutics Inc DNLI.O:

  • DENALI THERAPEUTICS ANNOUNCES TOPLINE RESULTS FOR REGIMEN G EVALUATING EIF2B AGONIST DNL343 IN THE PHASE 2/3 HEALEY ALS PLATFORM TRIAL

  • DENALI THERAPEUTICS INC - STUDY DID NOT MEET PRIMARY ENDPOINT OF SLOWING DISEASE PROGRESSION

  • DENALI THERAPEUTICS INC - DNL343 FOUND TO BE SAFE AND WELL TOLERATED

  • DENALI THERAPEUTICS INC - KEY SECONDARY ENDPOINTS NOT STATISTICALLY DIFFERENT AT WEEK 24

Source text: ID:nGNXbtw9Bj

Further company coverage: DNLI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI